The potential role of DES in peripheral in-stent restenosis

Journal of Cardiovascular Surgery

Volumn 51, Issue 4, 2010, Pages 561-565

  Zeller, T ^a   Macharzina, R ^a   Tepe, G ^b  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b Rosenheim Hospital   (Germany)

Author keywords

Coronary artery disease; Coronary restenosis; Drug eluting stents; Renal artery

Indexed keywords

CYPHER; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG; ZILVER PTX;

ANKLE BRACHIAL INDEX; ATHERECTOMY; CELL PROLIFERATION; DRUG ELUTING STENT; ECHOGRAPHY; HUMAN; IN-STENT RESTENOSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RENAL ARTERY; REVASCULARIZATION; REVIEW; SMOOTH MUSCLE FIBER; SUPERFICIAL FEMORAL ARTERY;

ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; FEMORAL ARTERY; HUMANS; POPLITEAL ARTERY; PROSTHESIS DESIGN; RECURRENCE; RENAL ARTERY OBSTRUCTION; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 78649313323     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006;354:1879-88.
2. Bosiers M, Torsello G, Gissler HM, Ruef J, Müller-Hülsbeck S, Jahnke T et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-mont results of DURABILITY I study. J Endovasc Ther 2009;16:261-9.
3. Katzen B, Laird J. The resilient trial: two-year update of outcomes. Presented at the International Symposium on Endovascular Therapy; January 2009; Hollywood, FL, USA.
4. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG et al; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease. Int Angiol 2007;26:81-157.
5. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: Long-term results from the SIROCCO trial. J Endovasc Ther 2006;13:701-10.
6. Lammer J, on behalf of the STRIDES investigators. First-in-human clinical trial of a nitinol self-expanding everolimus-eluting stent for prevention of restenosis following infrainguinal endovascular intervention: the STRIDES trial. Presented at the Cardiovascular and Interventional Radiological Society of Europe; September 2009; Lisbon, Portugal.
7. Dick P, Sabeti S, Mlekusch W, Schlager O, Amighi J, Haumer M et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology 2008;248:297-302.
8. Zeller T, Rastan A, Schwarzwälder U, Schwarz T, Frank U, Bürgelin K et al. Long-term Results after Directional Atherectomy of Femoro-popliteal Lesions. JACC 2006;48:1573-8.
9. Dake MD. Interim report on the Zilver PTX clinical trial. Paper presented at the International Society of Endovascular Therapy (ISET), 2010; Hollywood, FL, USA.
10. Scheinert D, Ulrich M, Scheinert S, Sax J, Bräunlich S, Biamino G, Schmidt A. Comparison of sirolimus-eluting vs. bare-metal stents for the treatment of infrapopliteal obstructions. Eurointervention 2006;2:169-74.
11. Siablis D, Kraniotis P, Karnabatidis D, Kagadis GC, Katsanos K, Tsolakis J. Sirolimus-eluting versus bare metal stents for bailout after suboptimal infrapopliteal angioplasty for chronic limb ischemia: 6 month angiographic results from a nonrandomized prospective single-center study. J Endovasc Ther 2005;12:685-95.
12. Bosiers M, Deloose K, Verbist J, Peeters P. Percutaneous transluminal angioplasty for the treatment of below-the-knee critical limb ischemia: Early outcomes following the use of sirolimus-eluting stents. J Cardiovasc Surg (Torino) 2006;47:171-6.
13. Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, Kraniotis P, Diamantopoulos A et al. Sirolimus-eluting versus bare stents for after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. J Endovasc Ther 2007;14:241-50.
14. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J et al.; ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71.
15. Zeller T, Frank U, Müller C, Bürgelin K, Schwarzwälder U, Horn B, Neumannn FJ. Farbduplexsonographie zur Verlaufskontrolle nach Stent-PTRA ostialer Nierenarterienstenose. Z Ultraschall Med 2002;23:315-9.
16. Zeller T, Rastan A, Schwarzwälder U, Müller C, Schwarz T, Frank U et al. Treatment of instent restenosis following stent-supported renal artery angioplasty. Cath Cardiovasc Intervent 2007;70:454-9.
17. Zeller T, Sixt S, Rastan A, Schwarzwälder U, Müller C, Noory E et al. Treatment of reoccurring instent restenosis following reintervention after stent-supported renal artery angioplasty. Catheter Cardiovasc Interv 2007;70:296-300.
18. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31:S1-S296.
19. Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
20. Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Böhm M et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003;24:1462-7.
21. Tepe G. Polymers: why not? Presented at the Cardiovascular and Interventional Radiological Society of Europe; September 2009;Lisbon, Portugal.
22. Rand T, Basile A, Cejna M, Fleischmann D, Funovisc M, Gschwendtner M et al. PTA versus carbofilm-coated stents in infrapopliteal arteries: pilot study. Cardiovasc Intervent Radiol 2006;29:29-38.